CNS Innovation: What It Takes to Win

Four conditions for translating scientific progress into patient impact and commercial value

Authors

The Four Conditions

Scientific progress is expanding what CNS therapies can target and deliver. For years, high failure rates and a blood-brain barrier that turned promising biology into stranded assets kept many developers cautious. Today, RNA-targeting medicines, new delivery platforms, and blood-based biomarkers are reopening opportunities that once seemed out of reach. But a promising mechanism is only one part of a viable product strategy. Developers must also establish where meaningful unmet need persists, whether clinical benefit justifies the full treatment burden, and how eligible patients will be identified and treated. At Trinity, we see these four conditions as a practical framework for evaluating which CNS innovations can translate into meaningful patient impact and sustainable commercial value. Here is what we are watching in each.

INSIGHT

Condition 1: Mature Markets Still Reward Meaningful Differentiation

Some of the largest, most genericized CNS markets keep proving there is still room for differentiated entrants, even decades after generics arrive. In psychiatry, Rexulti was first approved in 2015, yet it continues to deliver double-digit growth, powered by demand in major depressive disorder and a newer indication in agitation associated with dementia due to Alzheimer’s disease. In the first half of 2026, Lundbeck reported Rexulti revenue of >$500M, up 17% (Lundbeck).

Multiple sclerosis (MS) tells a similar story. Ocrevus entered an already crowded market in 2017, years after interferons and other established therapies, yet it became the first therapy approved for primary progressive MS and grew into the category’s clear commercial leader, generating roughly $2 billion in a single quarter by late 2024 (Pharmaceutical Technology; BioCentury).

Migraine has followed the same pattern. The rise of CGRP therapies shows that a large, symptomatic disease area can still reward a differentiated mechanism, particularly when patients experience the burden of disease daily and are motivated to seek out new options. Growth continues even within the class: Lundbeck reported first-half 2026 Vyepti revenue of ~$450M, up 46% (Lundbeck).

This is not guaranteed in every mature category and something that makes CNS particularly unique. As an example in a different therapeutic area, PCSK9 inhibitors delivered dramatic LDL-C reductions but struggled for years against inexpensive familiar statins, largely invisible disease burden, low physician urgency to treat, and payer friction (BioPharma Dive).

What distinguishes the CNS examples is that specific patient segments retain substantial, visible unmet need. Disease complexity, day-to-day symptom burden, and the toll on quality of life create durable pockets of need that are challenging to fully close. The implication is that maturity and genericization do not eliminate opportunity when a new therapy delivers a benefit that patients, caregivers, and clinicians can clearly recognize. The opportunity remains substantial, but unmet need alone does not guarantee adoption.

INSIGHT

Condition 2: Clinical Benefit Must Justify the Full Treatment Burden

Alzheimer’s disease illustrates both the challenge of the benefit-burden trade-off and the opportunity to improve it. There is intense need for disease-modifying therapy, but the amyloid-targeting antibodies approved to date deliver modest, incremental efficacy and require careful safety monitoring for amyloid-related imaging abnormalities (ARIA), including brain swelling and bleeding. Uptake has been slower than many sponsors expected, suggesting that much of the market has not yet accepted that burden for the benefit offered.

That trade-off is not fixed. In July 2026, the FDA approved Leqembi Iqlik as a once-weekly subcutaneous initiation dose, allowing patients to receive lecanemab by autoinjector from the start of treatment rather than through biweekly infusions (Biogen). The change reduces one component of treatment burden but does not remove the need for amyloid confirmation or MRI monitoring (FDA label). The commercial question is therefore not simply whether patients will accept today’s trade-off, but how effectively developers can improve it.

Parkinson’s disease shows the same principle from a different angle. AbbVie’s Vyalev, a continuous subcutaneous levodopa infusion, was approved specifically for adults with advanced Parkinson’s disease whose motor fluctuations are inadequately controlled (AbbVie). It reduces ‘off’ time by asking patients to accept additional administration complexity, in a population for whom that burden may be justified by the potential benefit.

The lesson is not that one disease area has succeeded and the other has not. Both have benefited from scientific advances. The critical question is whether efficacy, administration burden, safety, monitoring, and treatment setting align with what a specific population of patients, physicians, caregivers, and payers are prepared to accept.

That calculus varies by disease context. Patients may accept greater risk or inconvenience when disease is severe and progressive, but tolerance for safety risk, monitoring, and complex administration may be much lower in earlier or less symptomatic disease. The winning profile is therefore disease-specific and segment-specific: the same burden that is acceptable in one CNS population may sharply constrain adoption in another.

For developers, this means target product profile decisions cannot be separated from commercial strategy. The right question is not only whether a therapy can demonstrate a statistically significant benefit. It is whether that benefit is meaningful enough, in the intended population and treatment setting, to justify everything required to receive it. Defining the right product profile, however, is only useful if developers can build a therapy capable of delivering it.

INSIGHT

Condition 3: New Modalities and Delivery Technologies Expand What Is Possible

A critical scientific shift in CNS is not simply the discovery of new biology; it is the emergence of technologies that address two longstanding constraints: the difficulty of modulating the target and the difficulty of reaching it.

In regards to modulating the target, RNA-targeting small molecules are turning previously undruggable biology into oral, brain-penetrant medicines by acting directly on RNA, for example by stabilizing or disrupting RNA-protein interactions, biasing splicing outcomes, or driving degradation of pathogenic transcripts. Spinal muscular atrophy (SMA) is the precedent: the disease now supports an oral small molecule, an intrathecal antisense oligonucleotide (ASO), and a gene therapy, showing what is achievable when disease biology and modality options align.

Huntington’s disease offers an emerging test of this approach. In September 2026, Skyhawk Therapeutics reported encouraging 15-month clinical findings for its oral RNA-splicing modifier SKY-0515, alongside sustained reductions of more than 60% in mutant huntingtin protein at the higher dose (Skyhawk Therapeutics). The small dataset, with 15 participants assessed at Month 15, and the comparison with external natural-history controls limit conclusions, making confirmation in the ongoing placebo-controlled FALCON-HD program essential (HDBuzz). For developers, the significance is the possibility of combining molecular targeting with the accessibility of an oral therapy.

In regards to reaching the target, blood-brain barrier (BBB) delivery platforms are tackling a longstanding barrier to CNS drug development, and pharma increasingly values them as reusable infrastructure rather than capabilities tied to a single program. AbbVie’s $1.4 billion acquisition of Aliada Therapeutics, for example, secured a non-viral BBB-crossing platform alongside a lead Alzheimer’s program (Fierce Biotech).

Sangamo’s restructuring provides a more recent illustration. After earlier licensing deals with Astellas and Lilly for its STAC-BBB capsid, Sangamo filed for Chapter 11 in June 2026. The company has since confirmed that Lilly completed its $50 million acquisition of Sangamo’s capsid delivery, zinc finger, and modular integrase (MINT) platforms, together with its ST-506 prion disease program (Sangamo via StockTitan; SEC filing). The transaction covered a bundle of technologies rather than STAC-BBB alone, but it suggests continued strategic interest in these capabilities despite the originating company’s financial distress.

If these platforms deliver on their promise, they could meaningfully reduce delivery risk and allow developers to revisit validated targets that previously failed because the therapeutic could not reach the brain safely or consistently. Reaching the target, however, is not enough if the appropriate patients cannot be identified and brought into care.

INSIGHT

Condition 4: Diagnostic Readiness Turns Innovation into a Treatment Pathway

Better patient identification is becoming a commercial lever in CNS, not merely a diagnostic improvement. The value lies in creating an actionable pathway that identifies the right patient, at the right disease stage, with sufficient confidence to support treatment selection, reimbursement, and monitoring.

Spinal muscular atrophy provides a clear example. The adoption of SMA newborn screening across U.S. states moved identification toward the presymptomatic period, when treatment can have the greatest impact. Screening therefore helped create a time-sensitive treatment pathway, not simply a larger diagnosed population.

Alzheimer’s disease may be the next major test case. In May 2025, the FDA cleared Fujirebio’s Lumipulse G p-tau217/beta-amyloid 1-42 plasma-ratio test, the first blood-based diagnostic cleared to aid Alzheimer’s diagnosis. The landscape has broadened quickly since then. Roche’s Elecsys pTau181 was cleared in October 2025 to help rule out amyloid pathology in primary care, and in August 2026 the FDA cleared both Roche’s Elecsys pTau217 and C2N’s PrecivityAD2, bringing the number of cleared Alzheimer’s blood tests to four (Medical News Today). PrecivityAD2 is the first cleared for symptomatic adults as young as 40 and, like the others, is intended to complement clinical assessment rather than serve as a stand-alone diagnosis (Alzheimer’s Association).

The near-term opportunity is therefore not population screening, but a more scalable route to identifying symptomatic patients who warrant further evaluation. The practical question is now where each test belongs, from primary-care rule-out to specialist confirmation, within clinical assessment and referral pathways.

Molecularly defined diseases show the strategic endpoint. In SOD1-associated ALS, genetic testing identifies patients eligible for tofersen, while neurofilament light chain has supported regulatory and treatment-response evidence. In unexplained epilepsy, professional guidance increasingly supports broad genetic testing, creating opportunities to define more actionable, gene-specific patient segments.

The implication for developers is clear: diagnostic readiness should be evaluated alongside target biology and clinical profile. A strong asset can remain constrained if the relevant patients cannot be found, confirmed, referred, and treated through a practical care pathway. Conversely, advances in screening and biomarkers can help build scalable pathways that identify the biologically appropriate patient early enough for treatment to matter.

OUR PERSPECTIVE

Trinity’s View

Taken together, these four conditions point to the same conclusion. Scientific progress is creating real openings in CNS, but capturing them requires answering four questions in an integrated way. For developers and investors, we would start with:

1. Where does a clearly defined population still have meaningful unmet need?
2. What benefit would justify the therapy’s safety, monitoring, and administration requirements?
3. Which modality and delivery approach can achieve that profile?
4. Can the appropriate patients be identified and treated through a workable care pathway?

The next generation of CNS winners may therefore not be the companies pursuing the most novel biology. They may be the companies that best pair modality, delivery technology, patient identification, and a disease-specific target product profile. Novel biology may create the opening, but an integrated development and commercialization strategy will determine how much of that opportunity can be realized.

Amanda Francis, Partner

For more information about this perspective, contact us.